Diabetes Care
Predictors of Peak Body Weight Loss With Semaglutide in the SELECT Trial
Trial in 7,594 peopleSemaglutide
Papers by Steven Kahn
12 results
- European Heart Journal
Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial
Randomised trial in peopleSemaglutide - ADA Scientific Sessions 2026 Abstract
Serum Proteomics Suggest Novel Mechanisms of Action of Semaglutide in Reducing the Risk of MACE in the SELECT Trial
Trial in peopleInterventions
- ADA Scientific Sessions 2026 Abstract
Twenty-Year Glycemia Trajectories and Risk for Cognitive Impairment (CI) in Adults with Prediabetes or Type 2 Diabetes (T2D) in the Diabetes Prevention Program Outcomes Study (DPPOS)
Trial in peoplePopulations - ADA Scientific Sessions 2026 Abstract
Time-to-Event Nonadditive Analysis Identifies Novel Genetic Variants Associated with Treatment Response and Weight Loss in the GRADE Clinical Trial
Trial in peopleInterventions - ADA Scientific Sessions 2026 Abstract
Large-Scale Proteomic Discovery of Prognostic and Treatment-Responsive CKD Biomarkers in SELECT
Trial in peopleBiomarkers - ADA Scientific Sessions 2026 Abstract
Baseline Clinical and Proteomic Predictors of Glycemic Deterioration in SELECT
Trial in peopleBiomarkers - ADA Scientific Sessions 2026 Abstract
Molecular Basis of Type 2 Diabetes Prevention by Semaglutide in SELECT
Trial in peopleInterventions - ADA Scientific Sessions 2026 Abstract
Exploring Semaglutide's Effect on the ASCVD-Related Proteomic Signature and Their Prediction of MACE in SELECT
Trial in peopleInterventions - ADA Scientific Sessions 2025 Abstract
Genetic Variants Associated with Weight Change in Response to Glucose-Lowering Medications—Results from the GRADE Study
Trial in peopleInterventions